Valproate is a teratogenic drug,
SDM is the process of a healthcare professional (HCP) and patient working together to facilitate preference-based decisions and is one of the six quality statements set by the National Institute for Health and Care Excellence (NICE).
Valproate treatment for epilepsy can be detrimental to both fertility and pregnancy outcomes. It also impacts contraception choices, resulting in consultations that are complex and nuanced.